# KIORA PHARMACEUTICALS, INC. (KPRX) · Edgar & Edgarette company card

> Kiora Pharmaceuticals (KPRX) saw revenue fall 100% in FY2025 to $0 million, operating margin null against a -3.8% median for pharmaceutical preparations, equity 66.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1372514 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/KPRX) · [JSON](https://www.pops4.com/boards/company/KPRX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year 28.2%) |
| Net margin | -Infinity% |
| Operating cash flow | −$10M |
| Capital spending | $110,789 |
| Free cash flow | −$10M |
| Cash | $9M |
| Long-term debt | — |
| Total assets | $24M |
| Total equity | $16M |
| Equity ÷ assets | 66.5% |
| Return on equity | -67.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -17.3 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating loss: a margin of -Infinity% in FY2025; free cash flow was negative: capital spending outran operating cash (-$10.1M in FY2025)

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: revenue down 100.0% on the year; operating margin null, down from 28.2%. Soundness: equity 66.5% of assets, return on equity -67.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median; growth -100.0% against 13.7%.

Range logged 2026-09-20, receipt 6123a0703e1e2c68, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-09-08 ([filing](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/0001372514-26-000079-index.htm))

## Recent filings

- 8-K · filed 2026-10-29 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000088/0001372514-26-000088-index.htm)
- 8-K · filed 2026-09-08 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/0001372514-26-000079-index.htm)
- 8-K · filed 2026-08-19 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000077/0001372514-26-000077-index.htm)
- 8-K · filed 2026-08-07 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/0001372514-26-000075-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000074/0001372514-26-000074-index.htm)
- 8-K · filed 2026-06-18 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/0001372514-26-000063-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001372514.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1372514

## Cite

POPS4, Edgar & Edgarette: KIORA PHARMACEUTICALS, INC. (KPRX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/KPRX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.